Law360, New York (May 10, 2017, 8:25 PM EDT) -- Scott Gottlieb will start his tenure atop the U.S. Food and Drug Administration with oodles of hot-button policy questions demanding his attention, including deeply contentious issues involving drug safety and nutritional disclosures.
Gottlieb on Tuesday won U.S. Senate confirmation on a 57-42 vote. His credentials include a medical degree and a high post at the FDA during the George W. Bush administration, but his extensive business ties to drugmakers drew scrutiny and cost him many Democratic votes.
Scott Gottlieb is expected to take the FDA in a more conservative direction. (American Enterprise Institute) Here are key debates that attorneys expect Gottlieb...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!